VTv Receives Another U.S. Patent for Its Alzheimer’s Therapy Azeliragon

VTv Receives Another U.S. Patent for Its Alzheimer’s Therapy Azeliragon
VTv Therapeutics has received another U.S. patent for azeliragon, an Alzheimer’s treatment that targets a receptor involved in the disease's inflammation. Azekuragan is an antagonist of the advanced glycation endproducts, or RAGE, receptor, meaning that it prevents the receptor from acting. Found in low levels in a healthy brain, RAGE numbers increase during inflammation. The patent, number 9,717,710 (‘710), covers the use of 5 mg of azeliragon a day to treat people with mild cases of Alzheimer's. It runs through October 2034. VTv expects the U.S. Food and Drug Administration to add the patent to its Orange Book some day. That publication, whose official title is “Approved Drug Products with Therapeutic Equivalence Evaluations,” lists all drugs the FDA has approved, including their patent information. To make the book, of course, azeliragon will have to win FDA authorization. The patent is the latest in a number covering azeliragon, some of which deal with its formulations. VTv is "the only company developing a treatment for Alzheimer’s disease by targeting the RAGE receptor, which has demonstrated potential in addressing three key pathologies in Alzheimer's disease: amyloid-β, tau and chronic inflammation,” Steve Holcombe, the company's president and CEO, said in a press release. “This new patent is an important milestone as vTv prepares for the results of our upcoming Phase 3 [clinical trial] data readout.” Amyloid-β and tau are proteins assoc
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *